New dual monoclonal ELISA for measuring plasma osteopontin as a biomarker associated with survival in prostate cancer: Clinical validation and comparison of multiple ELISAs

Clinical Chemistry

Volumn 55, Issue 5, 2009, Pages 895-903

  Anborgh, Pieter H ^a   Wilson, Sylvia M ^a,i   Tuck, Alan B ^a,b,c   Winquist, Eric ^a,b   Schmidt, Nancy ^d,g   Hart, Russell ^d,g   Kon, Shigeyuki ^e,h   Maeda, Masahiro ^f   Uede, Toshimitsu ^e   Stitt, Larry W ^a,b   Chambers, Ann F ^a,b  

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c LONDON HEALTH SCIENCES CENTRE   (Canada)

^d Assay Designs Inc   (United States)

^e HOKKAIDO UNIVERSITY   (Japan)

^f Immuno Biological Laboratories Co Ltd   (Japan)

^g Luminos LLC   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPONTIN;

AMINO ACID SEQUENCE; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; PROGNOSIS; PROSTATE CANCER; PROTEIN BLOOD LEVEL; VALIDATION STUDY;

ANIMALS; ANTIBODIES, MONOCLONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MICE; MICE, INBRED BALB C; NEOPLASMS, HORMONE-DEPENDENT; OSTEOPONTIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 65949099324     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2008.117465     Document Type: Article

References (31)

1. Sodek J, Ganss B, McKee MD. Osteopontin. Crit Rev Oral Biol Med 2000;11:279-303.
2. Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br J Cancer 2004;90:1877-1881.
3. Tuck AB, Chambers AF, Allan AL. Osteopontin overexpression in breast cancer: knowledge gained and possible implications for clinical management. J Cell Biochem 2007;102:859-868 (Pubitemid 350036926)
4. Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta 2001;1552:61-85. (Pubitemid 34124131)
5. Suzuki M, Mose E, Galloy C, Tarin D. Osteopontin gene expression determines spontaneous metastatic performance of orthotopic human breast cancer xenografts. Am J Pathol 2007;171:682-692 (Pubitemid 47344699)
6. Singhal H, Bautista DS, Tonkin KS, O'Malley FP, Tuck AB, Chambers AF, Harris JF. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 1997;3:605-611 (Pubitemid 27211840)
7. Bramwell VH, Doig GS, Tuck AB, Wilson SM, Tonkin KS, Tomiak A, et al. Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res 2006;12:3337-3343
8. Hotte SJ, Winquist EW, Stitt L, Wilson SM, Chambers AF. Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer 2002;95:506-512
9. Ramankulov A, Lein M, Kristiansen G, Loening SA, Jung K. Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer. Prostate 2007;67:330-340 (Pubitemid 46255790)
10. Petrik D, Lavori PW, Cao H, Zhu Y, Wong P, Christofferson E, et al. Plasma osteopontin is an independent prognostic marker for head and neck cancers. J Clin Oncol 2006;24:5291-5297
11. Ramankulov A, Lein M, Kristiansen G, Meyer HA, Loening SA, Jung K. Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma. J Cancer Res Clin Oncol 2007;133:643-652 (Pubitemid 47077056)
12. Shimada Y, Watanabe G, Kawamura J, Soma T, Okabe M, Ito T, et al. Clinical significance of osteopontin in esophageal squamous cell carcinoma: comparison with common tumor markers. Oncology 2005;68:285-292
13. Plumer A, Duan H, Subramaniam S, Lucas FL, Miesfeldt S, Ng AK, Liaw L. Development of fragment-specific osteopontin antibodies and ELISA for quantification in human metastatic breast cancer. BMC Cancer 2008;8:38.
14. Vordermark D, Said HM, Katzer A, Kuhnt T, Hansgen G, Dunst J, et al. Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system. BMC Cancer 2006;6:207.
15. Bautista DS, Xuan JW, Hota C, Chambers AF, Harris JF. Inhibition of Arg-Gly-Asp (RGD)-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin. J Biol Chem 1994;269:23280-23285 (Pubitemid 24283318)
16. Xuan JW, Hota C, Chambers AF. Recombinant GST-human osteopontin fusion protein is functional in RGD-dependent cell adhesion. J Cell Biochem 1994;54:247-255 (Pubitemid 24081054)
17. Bautista DS, Saad Z, Chambers AF, Tonkin KS, O'Malley FP, Singhal H, et al. Quantification of osteopontin in human plasma with an ELISA: basal levels in pre- and postmenopausal women. Clin Biochem 1996;29:231-239
18. Kon S, Maeda M, Segawa T, Hagiwara Y, Horikoshi Y, Chikuma S, et al. Antibodies to different peptides in osteopontin reveal complexities in the various secreted forms. J Cell Biochem 2000;77:487-498
19. Slootstra JW, Puijk WC, Ligtvoet GJ, Langeveld JP, Meloen RH. Structural aspects of antibody-antigen interaction revealed through small random peptide libraries. Mol Divers 1996;1:87-96.
20. Williams SC, Badley RA, Davis PJ, Puijk WC, Meloen RH. Identification of epitopes within beta lactoglobulin recognised by polyclonal antibodies using phage display and PEPSCAN. J Immunol Methods 1998;213:1-17. (Pubitemid 28376591)
21. Bland JM, Altman DG. Applying the right statistics: analysis of measurement studies. Ultrasound Obstet Gynecol 2003;22:85-93. (Pubitemid 36886457)
22. Senger DR, Perruzzi CA, Papadopoulos A. Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res 1989;9:1291-1299 (Pubitemid 19277158)
23. Kon S, Yokosaki Y, Maeda M, Segawa T, Horikoshi Y, Tsukagoshi H, et al. Mapping of functional epitopes of osteopontin by monoclonal antibodies raised against defined internal sequences. J Cell Biochem 2002;84:420-432
24. Kazanecki CC, Uzwiak DJ, Denhardt DT. Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J Cell Biochem 2007;102:912-924 (Pubitemid 350036931)
25. Agnihotri R, Crawford HC, Haro H, Matrisian LM, Havrda MC, Liaw L. Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J Biol Chem 2001;276:28261-28267 (Pubitemid 37391532)
26. Chambers AF, Vanderhyden BC. Ovarian cancer biomarkers in urine. Clin Cancer Res 2006;12:323-327 (Pubitemid 43166116)
27. Ye B, Skates S, Mok SC, Horick NK, Rosenberg HF, Vitonis A, et al. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res 2006;12:432-441
28. Christensen B, Petersen TE, Sorensen ES. Post-translational modification and proteolytic processing of urinary osteopontin. Biochem J 2008;411:53-61.
29. Christensen B, Nielsen MS, Haselmann KF, Petersen TE, Sorensen ES. Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications. Biochem J 2005;390:285-292 (Pubitemid 41192254)
30. Christensen B, Kazanecki CC, Petersen TE, Rittling SR, Denhardt DT, Sørensen ES. Cell type-specific post-translational modifications of mouse osteopontin are associated with different adhesive properties. J Biol Chem 2007;282:19463-19472 (Pubitemid 47100061)
31. Masuda K, Takahashi N, Tsukamoto Y, Honma H, Kohri K. N-glycan structures of an osteopontin from human bone. Biochem Biophys Res Commun 2000;268:814-817 (Pubitemid 30150874)